The Manufacturers Life Insurance Company Takes Position in Ralliant Corporation $RAL

The Manufacturers Life Insurance Company bought a new position in shares of Ralliant Corporation (NYSE:RAL) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 99,840 shares of the company’s stock, valued at approximately $7,351,000. The Manufacturers Life Insurance Company owned approximately 0.09% of Ralliant at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Ralliant during the second quarter valued at approximately $1,039,481,000. Viking Global Investors LP purchased a new stake in Ralliant during the second quarter worth $257,200,000. State Street Corp purchased a new stake in Ralliant during the second quarter worth $213,096,000. Millennium Management LLC boosted its position in Ralliant by 172.4% during the 4th quarter. Millennium Management LLC now owns 4,973,001 shares of the company’s stock valued at $253,175,000 after acquiring an additional 3,147,660 shares in the last quarter. Finally, Flossbach Von Storch SE purchased a new position in shares of Ralliant in the 2nd quarter valued at $222,460,000.

Insider Buying and Selling at Ralliant

In related news, SVP Karen M. Bick sold 6,062 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $72.00, for a total value of $436,464.00. Following the completion of the transaction, the senior vice president owned 31,668 shares in the company, valued at $2,280,096. This trade represents a 16.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Tamara S. Newcombe sold 12,936 shares of Ralliant stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $71.79, for a total value of $928,675.44. Following the sale, the chief executive officer directly owned 251,967 shares of the company’s stock, valued at approximately $18,088,710.93. This represents a 4.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.42% of the stock is owned by corporate insiders.

Ralliant Trading Down 0.1%

Ralliant stock opened at $61.65 on Monday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.00 and a current ratio of 1.52. The stock has a market cap of $6.82 billion, a PE ratio of -5.68, a price-to-earnings-growth ratio of 2.29 and a beta of 1.61. The stock has a 50-day moving average of $68.40 and a two-hundred day moving average of $56.53. Ralliant Corporation has a one year low of $37.27 and a one year high of $75.41.

Ralliant (NYSE:RAL) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of $0.63 by $0.05. The business had revenue of $567.80 million for the quarter. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. On average, research analysts anticipate that Ralliant Corporation will post 2.87 EPS for the current fiscal year.

Ralliant Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Tuesday, September 8th will be issued a dividend of $0.05 per share. The ex-dividend date of this dividend is Tuesday, September 8th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Ralliant’s payout ratio is -1.84%.

Analysts Set New Price Targets

A number of brokerages recently weighed in on RAL. Oppenheimer upped their price objective on Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 13th. Truist Financial reiterated a “buy” rating and issued a $82.00 target price (up from $68.00) on shares of Ralliant in a report on Friday, July 31st. Citigroup increased their price target on shares of Ralliant from $81.00 to $82.00 and gave the company a “buy” rating in a research report on Friday, July 31st. TD Cowen raised their price target on shares of Ralliant from $70.00 to $80.00 and gave the company a “buy” rating in a report on Friday, July 31st. Finally, Evercore assumed coverage on shares of Ralliant in a report on Tuesday, June 9th. They issued an “outperform” rating and a $80.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Ralliant currently has an average rating of “Moderate Buy” and an average price target of $75.70.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.